TH-17 Cell-Related Cytokines' Potential Role in the Pathogenesis of Severe Asthma

References

• Bateman E D, Boushey H A, Bousquet J, Busse W W, Clark T J, Pauwels R A, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004; 170(8)836–844
   PubMed Web of Science ®Google Scholar
• Beasley R. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The Lancet 1998; 351(9111)1225–1232
   PubMed Web of Science ®Google Scholar
• Janson C, Anto J, Burney P, Chinn S, de Marco R, Heinrich J, et al. The European community respiratory health survey: what are the main results so far?. Eur Respir J 2001; 18(3)598–611
   PubMed Web of Science ®Google Scholar
• Bergeron C, Hauber H P, Gotfried M, Newman K, Dhanda R, et al. Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: effect of hydrofluoroalkane-flunisolide. J Allergy Clin Immunol 2005; 116(5)983–989
   PubMed Web of Science ®Google Scholar
• Ying S, Durham S R, Corrigan C J, Hamid Q, Kay A B. Phenotype of cells expressing mRNA for Th-2 type (interleukin 4 and interleukin 5) and Th-1 type (interleukin 2 and interferon gamma) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am J Respir Cell Mol Biol 1995; 12(5)477–487
   PubMed Web of Science ®Google Scholar
• Bradley B L, Azzawi M, Jacobson M, Assoufi B, Collins J V, Irani A M, et al. Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol 1991; 88(4)661–674
   PubMed Web of Science ®Google Scholar
• Robinson D S, Hamid Q, Ying S, et al. Predominant Th-2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326(5)298–304
   PubMed Web of Science ®Google Scholar
• Bentley A M, Meng Q, Robinson D S, Hamid Q, Kay A B, Durham S R. Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am J Respir Cell Mol Biol 1993; 8(1)35–42
   PubMed Web of Science ®Google Scholar
• Chakir J, Hamid Q, Bosse M, Boulet L P, Laviolette M. Bronchial inflammation in corticosteroid-sensitive and corticosteroid-resistant asthma at baseline and on oral corticosteroid treatment. Clin Exp Allergy 2002; 32(4)578–582
   PubMed Web of Science ®Google Scholar
• Carmichael J, Paterson I C, Diaz P, Crompton G K, Kay A B, Grant I W. Corticosteroid resistance in chronic asthma. Br Med J (Clin Res Ed) 1981; 282: 1419–1422
   PubMed Web of Science ®Google Scholar
• Barnes P J, Woolcock A J. Difficult asthma. Eur Respir J 1998; 12(5)1209–1218
   PubMed Web of Science ®Google Scholar
• Proceedings of the ATS workshop on refractory asthma. current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000; 162(6)2341–2351
   PubMedGoogle Scholar
• Busse W W, Banks-Schlegel S, Wenzel S E. Pathophysiology of severe asthma. J Allergy Clin Immunol 2000; 106(6)1033–1042
   PubMedGoogle Scholar
• Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F, et al. Asthma severity and medical resource utilisation. Eur Respir J 2004; 23(5)723–729
   PubMed Web of Science ®Google Scholar
• Sullivan S D, Rasouliyan L, Russo P A, Kamath T, Chipps B E. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy 2007; 62(2)126–133
   PubMed Web of Science ®Google Scholar
• The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003; 22(3)470–477
   PubMed Web of Science ®Google Scholar
• Romagnoli M, Caramori G, Braccioni F, Ravenna F, Barreiro E, Siafakas N M, et al. Near-fatal asthma phenotype in the ENFUMOSA Cohort. Clin Exp Allergy 2007; 37(4)552–557
   PubMed Web of Science ®Google Scholar
• Moore W C, Bleecker E R, Curran-Everett D, Erzurum S C, Ameredes B T, Bacharier L, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's severe asthma research program. J Allergy Clin Immunol 2007; 119(2)405–413
   PubMed Web of Science ®Google Scholar
• Cohen L, Tarsi X E J, Ramkumar T, Horiuchi T K, Cochran R, DeMartino S, et al. Epithelial cell proliferation contributes to airway remodeling in severe asthma. Am J Respir Crit Care Med 2007; 176(2)138–145
   PubMed Web of Science ®Google Scholar
• Shannon J, Ernst P, Yamauchi Y, Olivenstein R, Lemiere C, Foley S, et al. Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest 2008; 133(2)420–426
   PubMed Web of Science ®Google Scholar
• Lemière C, Ernst P, Olivenstein R, Yamauchi Y, Govindaraju K, Ludwig M S, et al. Airway inflammation assessed by invasive and noninvasive means in severe asthma: eosinophilic and noneosinophilic phenotypes. J Allergy Clin Immunol 2006; 118(5)1033–1039
   PubMed Web of Science ®Google Scholar
• Leung D Y, Hamid Q, Vottero A, Szefler S J, Surs W, Minshall E, et al. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med 1997; 186(9)1567–1574
   PubMed Web of Science ®Google Scholar
• Barnes P J, Adcock I M, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005; 25(3)552–563
   PubMed Web of Science ®Google Scholar
• Molet S M, Hamid Q A, Hamilos D L. IL-11 and IL-17 expression in nasal polyps: relationship to collagen deposition and suppression by intranasal fluticasone propionate. Laryngoscope 2003; 113(10)1803–1812
   PubMed Web of Science ®Google Scholar
• McKinley L, Alcorn J F, Peterson A, DuPont R B, Kapadia S, Logar A, et al. Th-17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008; 181: 4089–4097
   PubMed Web of Science ®Google Scholar
• Cua D J, Sherlock J, Chen Y, Murphy C A, Joyce B, Seymour B, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744–748
   PubMed Web of Science ®Google Scholar
• Babu K S, Davies D E, Holgate S T. Role of tumor necrosis factor alpha in asthma. Immunol Allergy Clin North Am 2004; 24: 583–597
   PubMed Web of Science ®Google Scholar
• Keatings V M, Collins P D, Scott D M, Barnes P J. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153: 530–534
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hocking R J, Atkins C J, Locksley R M, Stockinger B. TGF beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24: 179–189
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, Korn T, Strom T B, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH-17 and regulatory T cells. Nature 2006; 441: 235–238
   PubMed Web of Science ®Google Scholar
• Mangan P. R., Harrington L. E., O'Quinn D. B., Helms W. S., Bullard D. C., Elson C. O., et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006; 441: 231–234
   PubMed Web of Science ®Google Scholar
• Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13: 139–145
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, Korn T, Strom T B, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235–238
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Ghilardi N, Xie M H, de Sauvage F J, Gurney A L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278: 1910–1914
   PubMed Web of Science ®Google Scholar
• Bettelli E, Oukka M, Kuchroo V K. TH-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8(4)345–350
   PubMed Web of Science ®Google Scholar
• Harrington L E, Hatton R D, Mangan P R, Turner H, Murphy T L, Murphy K M, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123–1132
   PubMed Web of Science ®Google Scholar
• Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol 2007; 19(6)362–371, doi:10.1016/j.smim.2007.10.007
   PubMed Web of Science ®Google Scholar
• Ivanov I I, McKenzie B S, Zhou L, Tadokoro C E, Lepelley A, Lafaille J J, et al. The orphan nuclear receptor ROR gammat directs the differentiation program of proinflammatory IL-17(+) T helper cells. Cell 2006; 126: 1121–1133
   PubMed Web of Science ®Google Scholar